Patents by Inventor Michael R. Mish

Michael R. Mish has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240116946
    Abstract: The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
    Type: Application
    Filed: October 3, 2023
    Publication date: April 11, 2024
    Inventors: Stephen E. Ammann, Xinpei Cai, Eda Y. Canales, Weng K. Chang, Gregory F. Chin, Henok H. Kinfe, Scott E. Lazerwith, Jessica L. McKinley, Michael R. Mish, Devan Naduthambi, Jason K. Perry, Kevin X. Rodriguez, Scott D. Schroeder, Christopher J. Swank, Joshua J. Van Veldhuizen
  • Publication number: 20240116928
    Abstract: There is provided a compound of Formula (I): or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of wherein the various substituents are defined herein,
    Type: Application
    Filed: June 29, 2023
    Publication date: April 11, 2024
    Inventors: Mark J. Bartlett, Gregory F. Chin, Jennifer L. Cosman Ellis, Richard L. Mackman, Michael R. Mish
  • Patent number: 11919869
    Abstract: Provided herein is A compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the various substituents are described herein.
    Type: Grant
    Filed: October 27, 2022
    Date of Patent: March 5, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Mark J. Bartlett, Gregory F. Chin, Michael O. Clarke, Jennifer L Cosman, Deeba Ensan, Bindu Goyal, Stephen Ho, Richard L Mackman, Michael R. Mish, Dustin S. Siegel, Kyle C. Tamshen, Hai Yang
  • Publication number: 20240043427
    Abstract: The present disclosure provides pyrimidine dione compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors. The compounds can be used alone or in combination with other anti-cancer agents.
    Type: Application
    Filed: April 29, 2021
    Publication date: February 8, 2024
    Inventors: Mark J. Bartlett, Gregory F. Chin, Michael O. Clarke, Jennifer L. Cosman, Deeba Ensan, Bindu Goyal, Stephen Ho, Hon C. Hui, Richard L. Mackman, Michael R. Mish, Scott D. Schroeder, Nathan D. Shapiro, Dustin S. Siegel, Doris T. Tang, Hai Yang
  • Patent number: 11827609
    Abstract: This application relates generally to toll like receptor modulator compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR8), and methods of making and using them.
    Type: Grant
    Filed: August 11, 2021
    Date of Patent: November 28, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Gregory Chin, Richard L. Mackman, Michael R. Mish, Jeff Zablocki
  • Publication number: 20230295201
    Abstract: The present disclosure provides compounds for treating a variety of diseases, such as respiratory syncytial virus (RSV), HRV, hMPV, ebola, Zika, West Nile, Dengue, and HCV.
    Type: Application
    Filed: February 21, 2023
    Publication date: September 21, 2023
    Inventors: Daniel H. Byun, Gregory F. Chin, Byoung-kwon Chun, Michael O. Clarke, Bindu Goyal, Hon C. Hui, Petr Jansa, Richard L. Mackman, Michael R. Mish, Dustin S. Siegel, David Sperandio, Hai Yang, Lijun Zhang
  • Publication number: 20230183189
    Abstract: Provided herein is A compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the various substituents are described herein.
    Type: Application
    Filed: October 27, 2022
    Publication date: June 15, 2023
    Inventors: Mark J. Bartlett, Gregory F. Chin, Michael O. Clarke, Jennifer L. Cosman, Deeba Ensan, Bindu Goyal, Stephen Ho, Richard L. Mackman, Michael R. Mish, Dustin S. Siegel, Kyle C. Tamshen, Hai Yang
  • Publication number: 20230039553
    Abstract: The present disclosure provides pyrimidine dione compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors. The compounds can be used alone or in combination with other anti-cancer agents.
    Type: Application
    Filed: April 29, 2021
    Publication date: February 9, 2023
    Inventors: Mark J. Bartlett, Gregory F. Chin, Michael O. Clarke, Jennifer L. Cosman, Deeba Ensan, Bindu Goyal, Stephen Ho, Hon C. Hui, Richard L. Mackman, Michael R. Mish, Scott D. Schroeder, Nathan D. Shapiro, Dustin S. Siegel, Doris T. Tang, Hai Yang
  • Patent number: 11548901
    Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, X, W, Y1, Y2, Z1, and Z4 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: January 10, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Elizabeth M. Bacon, Zhenhong R. Cai, Xiaowu Chen, Jeromy J. Cottell, Manoj C. Desai, Mingzhe Ji, Haolun Jin, Scott E. Lazerwith, Michael R. Mish, Philip Anthony Morganelli, Hyung-Jung Pyun, James G. Taylor, Teresa Alejandra Trejo Martin
  • Publication number: 20220356196
    Abstract: The present disclosure provides compounds for treating a variety of diseases, such as respiratory syncytial virus (RSV), HRV, hMPV, ebola, Zika, West Nile, Dengue, and HCV.
    Type: Application
    Filed: February 16, 2021
    Publication date: November 10, 2022
    Inventors: Daniel H. Byun, Gregory F. Chin, Byoung-kwon Chun, Michael O. Clarke, Bindu Goyal, Hon C. Hui, Petr Jansa, Richard L. Mackman, Michael R. Mish, Dustin S. Siegel, David Sperandio, Hai Yang, Lijun Zhang
  • Publication number: 20220241281
    Abstract: The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating cancers.
    Type: Application
    Filed: October 8, 2021
    Publication date: August 4, 2022
    Inventors: Gregory Chin, Michael O`Neil Hanrahan Clarke, Xiaochun Han, Tim Hansen, Yunfeng Eric Hu, Dmitry Koltun, Ryan McFadden, Michael R. Mish, Eric Q. Parkhill, David Sperandio, Lianhong Xu, Hai Yang
  • Publication number: 20220218709
    Abstract: The present disclosure relates generally to toll like receptor modulator compounds, such as diamino pyrido[3,2 D] pyrimidine compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR-8), and methods of making and using them.
    Type: Application
    Filed: December 2, 2021
    Publication date: July 14, 2022
    Inventors: Evangelos Aktoudianakis, Gregory Chin, Richard L. Mackman, Samuel E. Metobo, Michael R. Mish, Hyung-Jung Pyun, Jeff Zablocki
  • Publication number: 20220073473
    Abstract: This application relates generally to toll like receptor modulator compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR8), and methods of making and using them.
    Type: Application
    Filed: August 11, 2021
    Publication date: March 10, 2022
    Inventors: Gregory CHIN, Richard L. MACKMAN, Michael R. MISH, Jeff ZABLOCKI
  • Patent number: 11179397
    Abstract: The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating cancers.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: November 23, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Gregory Chin, Michael O' Neil Hanrahan Clarke, Xiaochun Han, Tim Hansen, Yunfeng Eric Hu, Dmitry Koltun, Ryan McFadden, Michael R. Mish, Eric Q. Parkhill, David Sperandio, Lianhong Xu, Hai Yang
  • Publication number: 20210292348
    Abstract: The present disclosure describes 4?-fluoromethyl nucleosides for treating viral infections, including Dengue.
    Type: Application
    Filed: February 17, 2021
    Publication date: September 23, 2021
    Inventors: Daniel H. Byun, Gregory F. Chin, Michael O. Clarke, Bindu Goyal, Petr Jansa, Richard L. Mackman, Michael R. Mish, Dustin S. Siegel
  • Patent number: 11124487
    Abstract: This application relates generally to toll like receptor modulator compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR8), and methods of making and using them.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: September 21, 2021
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Gregory Chin, Richard L. Mackman, Michael R. Mish, Jeff Zablocki
  • Publication number: 20210053988
    Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, X, W, Y1, Y2, Z1, and Z4 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: May 6, 2020
    Publication date: February 25, 2021
    Inventors: Elizabeth M. Bacon, Zhenhong R. Cai, Xiaowu Chen, Jeromy J. Cottell, Manoj C. Desai, Mingzhe Ji, Haolun Jin, Scott E. Lazerwith, Michael R. Mish, Philip Anthony Morganelli, Hyung-Jung Pyun, James G. Taylor, Teresa Alejandra Trejo Martin
  • Publication number: 20210017170
    Abstract: The present disclosure provides methods for preparing (R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan-1-ol or a salt thereof and related key intermediates.
    Type: Application
    Filed: June 25, 2020
    Publication date: January 21, 2021
    Inventors: Evangelos Aktoudianakis, Andrea Ambrosi, Sylvie M. Asselin, Florence J. Bachrach, Pavel R. Badalov, Gregory F. Chin, Stephen P. Lathrop, Willard Lew, Richard L. Mackman, Jeffrey E. Merit, Samuel E. Metobo, Michael R. Mish, Beau P. Pritchett, Hyung-Jung Pyun, Christopher S. Regens, Tiago Vieira, Xianghong Wang, Adam B. Weinstein, Todd A. Wenderski, Zehua Zheng
  • Patent number: 10689399
    Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, X, W, Y1, Y2, Z1, and Z4 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: June 23, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Elizabeth M. Bacon, Zhenhong R. Cai, Xiaowu Chen, Jeromy J. Cottell, Manoj C. Desai, Mingzhe Ji, Haolun Jin, Scott E. Lazerwith, Michael R. Mish, Philip Anthony Morganelli, Hyung-Jung Pyun, James G. Taylor, Teresa Alejandra Trejo Martin
  • Patent number: 10640499
    Abstract: This application relates generally to toll like receptor modulator compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR8), and methods of making and using them.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: May 5, 2020
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Gregory Chin, Richard L. Mackman, Michael R. Mish, Jeff Zablocki